<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671174</url>
  </required_header>
  <id_info>
    <org_study_id>ILIFE Study</org_study_id>
    <nct_id>NCT03671174</nct_id>
  </id_info>
  <brief_title>Immunosuppressant Regimens for Living Fetuses Study</brief_title>
  <official_title>A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtuses (ILIFE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi No. 2 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of
      pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or
      guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based
      on the tendency to thrombosis formation and placental inflammation in the pathogenesis of
      UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without
      prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss
      patients with UCTD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To evaluate the effect of anticoagulation with or without immunomodulatory therapy
      on pregnancy outcomes of recurrent pregnancy loss with undifferentiated connective tissue
      diseases Design: a multi-center, randomised, open-label, paralleled study. Patients: Pregnant
      patients with recurrent pregnancy loss and undifferentiated connective tissue diseases
      without any known etiology for pregnancy loss (detailed in section 10).

      Methods: 420 selected patients are divided into 3 parallel groups (detailed in section 8).

      Randomization: Patients who present to relevant clinics for management of recurrent
      spontaneous abortion (RSA) will be evaluated for inclusion criteria and exclusion criteria by
      a formed physician. Once patient is eligible for the study, the co-investigator will obtain
      written patient's consent. Participants will be randomized into one of the 3 groups.
      Randomized numbers will be generated by pharmacology research personnel in Renji Hospital.
      Given the different administrated medications, neither the patient nor the provider will be
      blinded.

      Follow-up: Consultation will be scheduled every 4 weeks from confirmed pregnancy until
      delivery. The co-investigator will complete a follow-up survey including clinical, biological
      data.

      Missing data: Patients are willing to drop the study, unavailable, incompliant, with severe
      complications or with severe adverse effects. The missing data will be recorded in detail and
      be analysed with last pregnancy outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>After 28 weeks of gestation</time_frame>
    <description>Percentage of all cycles that lead to live birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of miscarriage</measure>
    <time_frame>Within 28 weeks of gestation</time_frame>
    <description>Spontaneous pregnancy loss within 28 weeks of gestation, confirmed by pelvic ultrasound findings. This includes no yolk sac or embryo in a gestational sac and an embryo without cardiac activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature birth</measure>
    <time_frame>between 28 and 37 weeks of gestations</time_frame>
    <description>live birth between 28 and 37 weeks of gestations Prematurity (live birth between 28 and 37 weeks of gestations); Eclampsia (new-onset hypertension after 20 weeks of gestation, +/- proteinuria &gt; 300mg/24h, with or without any organ damage with seizures); Fetal abnormality (congenital heart conduction block, neonatal lupus or malformation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth retardation</measure>
    <time_frame>between 28 and 37 weeks of gestations</time_frame>
    <description>weight below the 10th percentile for the gestational age Prematurity (live birth between 28 and 37 weeks of gestations); Eclampsia (new-onset hypertension after 20 weeks of gestation, +/- proteinuria &gt; 300mg/24h, with or without any organ damage with seizures); Fetal abnormality (congenital heart conduction block, neonatal lupus or malformation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age and weight at birth</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>the children's gestational age and weight at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 28 days</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>still alive at 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborns with treatment-related adverse events assessed by 3 parameters</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>assess the number of the newborns with abnormal vision, hearing and length at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital abnormality</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>congenital heart conduction block, neonatal lupus or malformation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eclampsia</measure>
    <time_frame>After 20 weeks of gestation</time_frame>
    <description>New-onset hypertension after 20 weeks of gestation, with or without proteinuria &gt; 300mg/24h, with or without any organ damage with seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Infection</measure>
    <time_frame>through study completion, an average of 1.5 years</time_frame>
    <description>Infection of respiratory tract, digestive tract, urinary tract and skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational diabetes mellitus</measure>
    <time_frame>through study completion, an average of 1.5 years</time_frame>
    <description>Clinical diagnosis of gestational diabetes mellitus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of UCTD</measure>
    <time_frame>through study completion, an average of 1.5 years</time_frame>
    <description>New onset or aggravation of symptoms like arthritis, rash, Reynolds phenomenon, proteinuria, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to systemic lupus erythematosus(SLE) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of systemic lupus erythematosus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to Sjogren's syndrome(SS) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of Sjogren's syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to systemic sclerosis(SSc) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of systemic sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to polymyositis(PM) or dermatomyositis(DM) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of polymyositis or dermatomyositis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to antiphospholipid syndrome (APS) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of antiphospholipid syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to rheumatoid arthritis (RA) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who evolved to mixed connective tissue disease(MCTD) from undifferentiated connective tissue diseases(UCTD)</measure>
    <time_frame>post-partum 6 weeks</time_frame>
    <description>Clinical diagnosis of mixed connective tissue disease</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Undifferentiated Connective Tissue Disease</condition>
  <condition>Recurrent Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>Prednisone + hydroxychloroquine + anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>10mg once daily orally</description>
    <arm_group_label>Prednisone + hydroxychloroquine + anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>100mg to 200mg twice daily orally</description>
    <arm_group_label>Hydroxychloroquine + anticoagulation</arm_group_label>
    <arm_group_label>Prednisone + hydroxychloroquine + anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>50mg once daily orally</description>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_label>Hydroxychloroquine + anticoagulation</arm_group_label>
    <arm_group_label>Prednisone + hydroxychloroquine + anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin</intervention_name>
    <description>Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous</description>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_label>Hydroxychloroquine + anticoagulation</arm_group_label>
    <arm_group_label>Prednisone + hydroxychloroquine + anticoagulation</arm_group_label>
    <other_name>Enoxaparin</other_name>
    <other_name>Dalteparin</other_name>
    <other_name>Nadroparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Women who meet the following inclusion criteria will be eligible to participate in the
        study:

          1. At reproductive age (20-40 years old).

          2. Trying to conceive.

          3. Diagnosed with UCTD[2]: at least one symptoms or signs suggesting connective tissue
             disease(CTD) and with at least one presence of auto-antibodies, including antinuclear
             antibody (ANA), anti-SSA antibody, while not fulfilling any classification criteria of
             a defined CTD.

          4. Diagnosed with RSA[39]: two or more failed pregnancies of unknown origin.

          5. Providing written informed consent. Exclusion criteria

        Women who meet any of the following criteria will be excluded from the study:

        1.Any known etiology of previous pregnancy loss:

          1. Diagnosis of antiphospholipid antibody syndrome.

          2. Known paternal, maternal or embryo chromosome abnormality.

          3. Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian
             syndrome; premature ovarian failure (follicle stimulating hormone, FSH ≥20uU/L in
             follicular phase); hyperprolactinemia; thyroid disease; diabetes mellitus; other
             hypothalamic-pituitary-adrenal axis abnormality.

          4. Maternal anatomical abnormality: uterine malformation; Asherman syndrome; cervical
             incompetence; uterine fibrosis more than 5 cm.

          5. Vaginal infection. 2.Any known severe cardiac, hepatic, renal, hematological or
             endocrinal diseases:

        (1)Alanine transaminase (ALT) or aspartate transaminase(AST) more than twice the upper
        limit of normal.

        (2)Clearance of creatinine less than 30mL/min. (3)Leucocytes less than 2.5*10^9/L, or
        Hemoglobine less than 85g/L, or Platelet less than 50~10^9/L.

        3.Any active infection:

          1. Active viral hepatitis including hepatitis B virus (HBV), hepatitis C virus (HCV).

          2. Active infection including V aricella-zostervirus(VZV), human immunodeficiency virus
             (HIV), syphilis or tuberculosis.

        4.Allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin or aspirin.

        5.Disease history as follows:

          1. Past history of digestive ulcers or upper gastrointestinal hemorrhage.

          2. Past history of malignancy.

          3. Past history of epilepsia or psychotic disorders. 6.Woman unable to consent or
             impossible to follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjing Lu</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangjing Lu</last_name>
    <phone>+86 13661472001</phone>
    <email>lu_liangjing@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangjing Lu</last_name>
      <phone>+8613661472001</phone>
      <email>lu_liangjing@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaoying Yang</last_name>
      <phone>+8613601984013</phone>
      <email>shaoying_yang@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999 Sep-Oct;17(5):615-20. Review.</citation>
    <PMID>10544849</PMID>
  </reference>
  <reference>
    <citation>Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, Tektonidou M, Yavuz S, Boumpas D, Tincani A. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770. Epub 2016 Jul 25.</citation>
    <PMID>27457513</PMID>
  </reference>
  <reference>
    <citation>Spinillo A, Beneventi F, Caporali R, Ramoni V, Montecucco C. Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association? Am J Reprod Immunol. 2017 Dec;78(6). doi: 10.1111/aji.12762. Epub 2017 Sep 16. Review.</citation>
    <PMID>28921728</PMID>
  </reference>
  <results_reference>
    <citation>Alarcón GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE, Billingsley LM, Luggen ME, Polisson RP, Willkens RF, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol. 1991 Sep;18(9):1332-9.</citation>
    <PMID>1757934</PMID>
  </results_reference>
  <results_reference>
    <citation>Laczik R, Soltesz P, Szodoray P, Szekanecz Z, Kerekes G, Paragh G, Rajnavölgyi E, Abel G, Szegedi G, Bodolay E. Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. Rheumatology (Oxford). 2014 Nov;53(11):2035-43. doi: 10.1093/rheumatology/keu236. Epub 2014 Jun 10.</citation>
    <PMID>24917564</PMID>
  </results_reference>
  <results_reference>
    <citation>Spinillo A, Beneventi F, Locatelli E, Ramoni V, Caporali R, Alpini C, Albonico G, Cavagnoli C, Montecucco C. The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study. BMC Pregnancy Childbirth. 2016 Oct 18;16(1):313.</citation>
    <PMID>27756248</PMID>
  </results_reference>
  <results_reference>
    <citation>Mosca M, Neri R, Strigini F, Carmignani A, Totti D, Tavoni A, Bombardieri S. Pregnancy outcome in patients with undifferentiated connective tissue disease: a preliminary study on 25 pregnancies. Lupus. 2002;11(5):304-7.</citation>
    <PMID>12090565</PMID>
  </results_reference>
  <results_reference>
    <citation>Spinillo A, Beneventi F, Epis OM, Montanari L, Mammoliti D, Ramoni V, Di Silverio E, Alpini C, Caporali R, Montecucco C. The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. Am J Obstet Gynecol. 2008 Dec;199(6):632.e1-6. doi: 10.1016/j.ajog.2008.05.008. Epub 2008 Jul 29.</citation>
    <PMID>18667193</PMID>
  </results_reference>
  <results_reference>
    <citation>Alijotas-Reig J, Ferrer-Oliveras R; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012 Jun;21(7):766-8. doi: 10.1177/0961203312440058.</citation>
    <PMID>22635227</PMID>
  </results_reference>
  <results_reference>
    <citation>Proietta M, Ferrero S, Ferri L, Cifani N, Bruno G, Del Porto F. Recurrent miscarriages in women not fulfilling classification criteria for antiphospholipid antibody syndrome. Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):429-32.</citation>
    <PMID>25280034</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, Barros R, Santos MJ, Sousa E, Barcelos A, Inês L. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009 Aug;28(8):915-21. doi: 10.1007/s10067-009-1175-2. Epub 2009 Apr 24.</citation>
    <PMID>19390908</PMID>
  </results_reference>
  <results_reference>
    <citation>Bansal AS. Joining the immunological dots in recurrent miscarriage. Am J Reprod Immunol. 2010 Nov;64(5):307-15. doi: 10.1111/j.1600-0897.2010.00864.x. Review.</citation>
    <PMID>20528832</PMID>
  </results_reference>
  <results_reference>
    <citation>Tempfer CB, Kurz C, Bentz EK, Unfried G, Walch K, Czizek U, Huber JC. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril. 2006 Jul;86(1):145-8. Epub 2006 May 23.</citation>
    <PMID>16716321</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomaa MF, Elkholy AG, El-Said MM, Abdel-Salam NE. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet. 2014 Oct;290(4):757-62. doi: 10.1007/s00404-014-3262-0. Epub 2014 May 13.</citation>
    <PMID>24818590</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol. 2000 Jan;27(1):41-6.</citation>
    <PMID>10648016</PMID>
  </results_reference>
  <results_reference>
    <citation>Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.</citation>
    <PMID>17075810</PMID>
  </results_reference>
  <results_reference>
    <citation>Koh JH, Ko HS, Kwok SK, Ju JH, Park SH. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015 Feb;24(2):210-7. doi: 10.1177/0961203314555352. Epub 2014 Oct 10.</citation>
    <PMID>25305214</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo Y, Zhang L, Fei Y, Li Y, Hao D, Liu Y, Zhao Y. Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. Clin Rheumatol. 2015 Oct;34(10):1721-8. doi: 10.1007/s10067-015-3050-7. Epub 2015 Aug 26.</citation>
    <PMID>26384980</PMID>
  </results_reference>
  <results_reference>
    <citation>Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016 Feb;214(2):273.e1-273.e8. doi: 10.1016/j.ajog.2015.09.078. Epub 2015 Sep 30.</citation>
    <PMID>26429521</PMID>
  </results_reference>
  <results_reference>
    <citation>Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, Salmon JE, Buyon JP. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010 Oct;69(10):1827-30. doi: 10.1136/ard.2009.119263. Epub 2010 May 6.</citation>
    <PMID>20447951</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Liangjing Lu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Undifferentiated Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

